Nephrodite

Executive Summary

Nephrodite is addressing the significant unmet need in end-stage kidney disease (ESKD) by developing Holly, the first implantable dialysis platform. Traditional dialysis imposes severe lifestyle restrictions, requiring patients to spend hours tethered to machines multiple times per week. Holly's continuous blood filtration system is designed to free patients from fixed schedules, enabling mobility and a near-normal quality of life. The device represents a paradigm shift from episodic to continuous therapy, potentially reducing complications and improving outcomes. Currently, Holly is an investigational device with no regulatory approval. Nephrodite, a private company founded in 2017 and based in San Francisco, must navigate clinical trials and FDA clearance. While the technology has transformative potential, significant execution risks remain, including trial enrollment, safety validation, and manufacturing scale-up. If successful, Holly could disrupt the $80+ billion dialysis market; however, investors should monitor regulatory milestones and partnerships closely.

Upcoming Catalysts (preview)

• Q3 2026FDA Approval of Investigational Device Exemption for Pivotal Trial70% success
• Q4 2026Interim Clinical Data Readout from First-in-Human Study60% success
• Q2 2026Strategic Partnership with Major Dialysis Provider50% success